Vanderbilt Univ Med Ctr — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$93,906	1
2024	Research	$24,197	11
2023	Research	$41,622	25
2022	Research	$68,334	83
2019	Research	$259,939	53

Breakdown

Who paid Research payments · program years 2019–2025

Incyte Corporation $259,939 53 payments
Mentor Worldwide LLC $132,738 118 payments
GlaxoSmithKline, LLC. $93,906 1 payment
Stryker Corporation $1,414 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 1 Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies $170,646 31 payments
A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction $132,738 118 payments
Study name not reported $93,906 1 payment
A Study of Ruxolitinib vs Best Available Therapy BAT in Patients With Steroid refractory Chronic Graft vs Host Disease GvHD After Bone Marrow Transplantation REACH3 $79,789 8 payments
A Phase 1,2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage 3B or Stage 4 Non Small Cell Lung Cancer and Stage 4 Microsatellite Stable Colorectal Cancer $5,119 8 payments
A Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies $2,540 4 payments
A Phase 1, 2, Open Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors, ECHO 207KEYNOTE 723 $1,845 2 payments
Infinity With Adaptis Technology Total Ankle Replacement Follow-Up (Itar2) $1,414 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.